New indications for Arixtra® in the United States: the treatment of acute deep venous thrombosis and acute pulmonary emb
New indications for Arixtra® in the United States: the treatment of acute deep venous thrombosis and acute pulmonary embolism. Paris, June 4, 2004 Sanofi-Synthelabo announced today that the synthetic, selective factor Xa inhibitor Arixtra® (fondaparinux sodium) has been approved by the US Food and Drug Administration (FDA) for two new indications: · the treatment of acute deep venous thrombosis when administered in conjunction with warfarin sodium, and · the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in